

Testosterone insufficiency in human immunodeficiency virus (HIV) infected women

Published: 13-11-2007

Last updated: 11-05-2024

To explore the prevalence of testosterone insufficiency in HIV-infected women and the associated sexual problems, fatigue , depression and quality of life.

Ethical review	Approved WMO
Status	Pending
Health condition type	Other condition
Study type	Observational invasive

Summary

ID

NL-OMON32221

Source

ToetsingOnline

Brief title

TI-study

Condition

- Other condition

Synonym

testosterone deficiency among HIV infected women

Health condition

Mogelijke insufficiëntie van testosteron bij HIV infectie

Research involving

Human

Sponsors and support

Primary sponsor: Academisch Medisch Centrum

Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: Hiv infected women, insufficiency, testosterone

Outcome measures

Primary outcome

Hormones: testosteron and SHBG

Secondary outcome

Questionnaires: FSFI, FSDS, SF36/MFI-20, SCL-90.

Study description

Background summary

Little is known about the prevalence of testosterone insufficiency and the associated problems in HIV-infected women. Among HIV infected men is the correlation between testosterone insufficiency and the associated factors described. The treatment in these men is effective.

Study objective

To explore the prevalence of testosterone insufficiency in HIV-infected women and the associated sexual problems, fatigue , depression and quality of life.

Study design

A cross-sectional design.

Study burden and risks

Because the extra blood will taken at the same moment as the standard blood we expect no extra risks. The questionnaire will take 30 minutes.

Contacts

Public

Academisch Medisch Centrum

meibergdreef 9
1105 AZ amsterdam
Nederland

Scientific

Academisch Medisch Centrum

meibergdreef 9
1105 AZ amsterdam
Nederland

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Female

HIV-infected

At least 18 year of age

Able and willing to provide informed consent

Understanding of Dutch or English language

Exclusion criteria

Androgen therapy during the 6 months prior to study start

Lactation and/or pregnancy in the 6 months prior to study start

Thyroid disease; hypo * or hyperthyroidism

Inability to understand questionnaire
Transgender hormonal/surgical therapies in past
Ovariectomy or radiation of the ovaries

Study design

Design

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 01-11-2007

Enrollment: 80

Type: Anticipated

Ethics review

Approved WMO

Application type: First submission

Review commission: METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register

CCMO

ID

NL20222.018.07